1. Home
  2. QCLS vs NCEL Comparison

QCLS vs NCEL Comparison

Compare QCLS & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Q/C Technologies Inc.

QCLS

Q/C Technologies Inc.

HOLD

Current Price

$2.62

Market Cap

22.1M

Sector

Health Care

ML Signal

HOLD

NCEL

NewcelX Ltd. Ordinary Shares

N/A

Current Price

$3.25

Market Cap

22.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QCLS
NCEL
Founded
2014
2008
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.1M
22.0M
IPO Year
2013
2019

Fundamental Metrics

Financial Performance
Metric
QCLS
NCEL
Price
$2.62
$3.25
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
140.7K
8.5K
Earning Date
04-15-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
22.33
N/A
EPS
N/A
N/A
Revenue
$3,929,527.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
32.71
N/A
52 Week Low
$2.50
$1.83
52 Week High
$8.17
$5.12

Technical Indicators

Market Signals
Indicator
QCLS
NCEL
Relative Strength Index (RSI) 35.43 43.95
Support Level $2.50 $3.02
Resistance Level $3.96 $3.66
Average True Range (ATR) 0.17 0.24
MACD 0.01 -0.00
Stochastic Oscillator 8.33 26.17

Price Performance

Historical Comparison
QCLS
NCEL

About QCLS Q/C Technologies Inc.

Q/C Technologies Inc is engaged in building blockchain and cryptocurrency infrastructure that is faster and more energy-efficient through quantum-class laser-based computing. The company uses laser-based processors inspired by quantum technology that can solve complex problems. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.

Share on Social Networks: